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Abstract
Nowadays there is a tendency towards the spread of viral diseases that cause significant complications to human health. There-
fore, the question of creating new drugs that have a high antiviral effect is topical.
The aim. To study the range of drugs in Ukraine for the treatment of herpes viral diseases.
Materials and methods. In the work were used the list of drugs from official sources of information, which were processed by 
methods of generalization, systematization, graphic, comparative and structural analysis.
Results and discussion. The marketing research of drugs for the treatment of herpes viral diseases presented at the pharmaceu-
tical market of Ukraine has been conducted. According to the results it is found that 80 drugs for the treatment of herpes viral diseases 
of various dosage forms are presented in the domestic market, of which 70 % – tablets; 51 % – medicines produced by the industry of 
Ukraine; 94 % – are monocomponent preparations.
Soft drugs play important role in the treatment of skin diseases because they provide a direct effect of the drugs on the patho-
gens, eliminate inflammatory phenomena and eliminate or reduce the symptoms of the disease. Soft dosage drugs have practically no 
contraindications, they can be used at any age, regardless of the presence of comorbidities.
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Conclusions. Domestic drugs (51 % of the total range) dominate in the market structure. The main part (94 %) consist of 
monocomponent preparations. The results of the research prove the relevance of the development of new combined soft dosage forms 
for the treatment of herpes viral diseases, which should be produced by the Ukrainian industry and satisfy the medical and econom-
ical needs of patients. The results of the marketing analysis show that it is relevant and promising to create new combined the soft 
dosage forms for the treatment of herpes viral diseases.
Keywords: pharmaceutical market, herpes viral diseases, assortment analysis, soft dosage forms.
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1. Introduction
Herpes viral diseases are among the most common diseases in the world, which is a leading 
medical and social problem [1, 2]. According to the WHO studies, about 80–90 % of the world’s 
population are infected with one or more types of herpes virus [3, 4]. The number of patients with 
herpes viral infections annually increases by 10 % [5, 6]. In Europe, the third of the population is 
suffering from herpes viral diseases [7, 8].
Due to the immunosuppressive effect of herpes viruses, the immune system is impaired, 
which gradually leads to chronic infection and possible damage to various organs and systems 
(eyes, liver, mucous membranes, skin, CNS), as well as the ability to replicate in all “host” cells 
(leukocytes, monocytes, fibroblasts) [9, 10]. Viruses are capable of triggering apoptosis – a ge-
netic program of cell death that also contributes to the development of diseases of the internal 
organs [11].
Herpes diseases are more commonly manifested in skin lesions that occur around the mouth, 
nose and ears. Initially occurs itching, burning and pain. After 1–2 days, small, transparent vesicles 
appear in groups.On the 3rd-4th day the bubbles dry up, in their place crusts are formed, which af-
ter 5–7 days fall away. Sometimes the bubbles merge and then flake off to produce surface erosion, 
which gradually heals without changes in skin.
Skin lesions in herpes viral infection may be zosterroform, hemorrhagic, hemorrhagic-ne-
crotic or ulcer-necrotic.
For the pharmacotherapy of viral infections, the following drugs are used: etiotropic, patho-
genetic and symptomatic [12]. The etiotropic drugs include acyclic guanosine analogues, inter-
ferons and immunoglobulins. Leading place among the etiotropic approaches is antiviral therapy, 
represented by a large group of acyclic nucleoside analogues – acyclovir, valacyclovir, famciclovir, 
etc. Immunotherapy for herpes viral infections, which use interferon and immunoglobulin prepa-
rations, is an additional component of etiotropic therapy [13, 14].
Pathogenetic drugs for the treatment of herpes viral infections are represented by various 
pharmacological groups: immunomodulators, non-steroidal anti-inflammatory drugs, antihista-
mines, antiseptic drugs, multivitamin drugs. Non-steroidal anti-inflammatory drugs, adaptogens, 
and antioxidants include symptomatic drugs that affect concomitant symptoms [15, 16].
At the pharmaceutical market of Ukraine, drugs for the treatment of herpes viral diseas-
es should present with a wide range and various dosage forms, which enable the doctor and the 
patient to choose the drug taking into the location of the lesion, the effectiveness and safety of 
the drug and the financial capacity of patient. Drugs for the treatment of herpes viral diseases 
in skin lesions should present with the soft dosage forms that are topical in the treatment of 
skin [17, 18].
Due to the large spread of herpes viral infections, their lifelong persistence in the hu-
man body, reactivation against the background of immunodeficiency and the development of 
various complications, creating of new drugs for the treatment of the above pathology remains 
relevant [19].
Therefore, it was important to research the segment of medicines for the treatment of herpes 
viral diseases at the pharmaceutical market of Ukraine and determine which dosage forms are 
available in most and which are limited.
The aim of the research. The aim of the work was to research of the segment of the drug 
market for the treatment of herpes viral diseases, presented at the pharmaceutical market of Ukraine 
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in 2019, to substantiate the feasibility of creating and introducing new drugs into the range of man-
ufacturing enterprise.
2. Materials and methods
The subjects of the study were selected registered drugs at the pharmaceutical market of 
Ukraine which use in the pharmacotherapy of herpes viral diseases. The study used data from the 
State Register of Medicines of Ukraine and data from the electronic directory – “Compendium- 
Medicines” [20]. During the study were applied methods of generalization, systematization, graph-
ical, comparative and structural analysis. The data obtained are systematized and clearly presented 
in the diagrams with explanations and conclusions.
3. Research results
In the course of marketing research, a step-by-step analysis of the drugs used for the treat-
ment of herpes viral diseases by dosage forms, countries of origin and a combination of active sub-
stances was carried out. The obtained data showed that in the domestic market in 2019, 80 names of 
medicines for the treatment of herpes viral diseases are presented. The analysis of the assortment 
of these drugs by the forms of issue are presented in Fig. 1.
As can be seen from the figure, the most common dosage form are tablets (70 %). Also at 
the pharmaceutical market of Ukraine are available syrups (11 %), powders and capsules 4 % each, 
drops (2 %), lyophilisate for solution for infusions (1 %). The proportion of the soft dosage forms in 
the study group is 8 %, namely in the form of cream – 6 %, ointments – 2 %.
Fig. 1. Propositions of dosage forms of drugs for the treatment of  
herpes viral diseases
The next stage of the researching was the study of drugs by producing countries. The distri-
bution of drugs is shown in Fig. 2.
Fig. 2. The diagram of the ratio of drugs for the treatment of herpes viral diseases on the 
manufacturing country
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It is established that by number of drugs the first place belongs to Ukraine (51 %). Offers to 
the pharmaceutical market also come from Germany (14 %), Poland (11 %). Assortment of drugs 
is presented by Hungary – 5 %, Slovenia, Cyprus, Russia, Italy – 4 % each, Canada, Great Britain 
and Romania – 1 % each.
Domestic manufacturers offer generic drugs at the pharmaceutical market of Ukraine: tab-
lets – 35 %, syrups – 6 %, capsules – 4 %, drops – 3 %, powders, ointments and creams – 1 % each.
Tablets of domestic production are represented by the following trade names: “Acyclovir- 
ASTRAFARM” (LLC “ASTRAFARM”), “Acyclovir-FARMAK” (PJSC “Pharmak”), “Acy-
clovir-Darnitsa” (JSC “Pharmaceutical company “Darnitsa”), “Acyclovir” (PJSC “Lekhim- 
Kharkiv”), “Herpevir®” (PJSC “Kievmedpreparat”), “Valavir®” (PJSC “Pharmak”), “Valtro-
vir®” (PJSC “Kievmedpreparat”), “Gropivirin” (PJSC “Pharmak”), “Novirin” (JSC “Kiev Vi-
tamin Plant”), “Groprim” (LLC “ASTRAFARM”), “Amiksin® IC” (Additional Liability Com-
pany “INTERCHEM”), “Amizon®” (JSC “Farmak”), “Erebra®” (JSC “Technologist”).
6 % are syrups: “Neoprinosin” (LLC “DKP “Pharmaceutical Factory”), “Novirin” (JSC 
“Kiev Vitamin Plant”), “Flavozid®” (PJSC “Pharmak”). The following position is occupied by 
capsules (4 %): “Nuclex” (LLC “Pharma Start”). 3 % are drops: “Proteflazid®” (LLC “NVK “Eco- 
pharm”).
The domestic drugs in the form of powders are represented by the preparations: “Herpevir®” 
(PJSC “Kievmedpreparat”). The range of soft dosage drugs are presented in the form of ointment 
(“Herpevir®” (PJSC “Kievmedpreparat”) and cream (“Agerp” (Joint Ukrainian-Spanish compa- 
ny “SperkoUkraine”).
According to the results of the analysis of the assortment of foreign drugs by the tablets 
forms make 35 %, creams and syrups – 5 % each, powders – 2 %, lyophilisate for the manufacture 
of solutions for infusions and syrups – 1 % each.
The range of foreign drugs in the form of tablets for the treatment of herpes viral dis-
eases is represented by the following trade names: “ZoviraxTM” (GlaxoSmithKlein Pharma-
ceuticals SA, Poland), “Acyk®” (Salutas Pharma GmbH, Germany), “Acyclovir stada®” (STA-
DA Artzneimtitel AG, Germany), “Virolex” (KRKA, d.d., Novo mesto, Slovenia), “Geviran” 
(POLFARMA SA, Poland), “Medovir” (Medokemi LTD, Cyprus), “Valtsik” (Pharmaceuticals 
Inc., Canada), “ValtrexTM” (GlaxoSmithKlein Pharmaceuticals SA, Poland), “Groprinosin®” 
(LLC “Gedeon Richter Poland”, Poland), “Izoprynozyn” (BP Teva Pharmaceutical Facto-
ry, Hungary), “Normomed” (JSC “Obninsk chemical and pharmaceutical company”, Rus- 
sian Federation).
The next position after tablets is occupied by creams and syrups (5 % each). The fol-
lowing trade names are presented in cream form: “Acyk®” (Salutas Pharma GmbH, Germany), 
“Virolex” (KRKA, d.d., Novo mesto, Slovenia), “ZoviraxTM” (Glaxo Operations UK Limited, 
Great Britain), “Acyclostad®” (STADA Artzneimtitel AG, Germany). Syrups are represented 
by the following trade names: “Groprinosin®-Richter” (Gideon Richter Romania A.T., Roma-
nia), “Neoprinosin” (LLC “Aflopharm Pharmacy Polish”, Poland), “Normomed” (ABC Phar-
macieutic SP, Italy).
Powders (2 %) are represented by the following preparations: “Virolex” (KRKA, d.d., Novo 
mesto, Slovenia), “Medovir” (Medokemi LTD, Cyprus). Also available at the pharmaceutical mar-
ket of Ukraine are lyophilisate for the manufacture of infusion solutions “ZoviraxTM” (GlaxoSmith-
Klein Manufacturing SPA, Italy) and syrups – “Groprinosin®-Richter” (Gideon Richter Roma- 
nia A.T., Romania), “Neoprinosin” (LLC “Aflopharm Pharmacy Polish”, Poland), “Normomed” 
(ABC Pharmacheutici SPA, Italy).
The results of marketing research show that 94 % of drugs are monocomponents (Fig. 3).
Based on consideration of combinations of active substances of investigated drugs for 
the treatment of herpes viral diseases, it is noted that the combined drugs make up a small 
amount (6 %) and are all of domestic production: “Flavozid®” (PJSC “Pharmak”), “Prote-
f lazid®” (LLC “NVK “Ecopharm”).
According to the results of the study, a macrocontour of the pharmaceutical market segment 
of drugs for the treatment of herpes viral diseases was constructed (Fig. 4).
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Fig. 3. Analysis of the range of drugs for the treatment of herpes viral diseases by  
the combination of active substances
Fig. 4. Macrocontour of the pharmaceutical market segment of drugs used to the treatment of 
herpes viral diseases
According to the results of the studies it was found that the most common dosage form in the 
treatment of herpes viral diseases are tablets (70 %); 51 % of the drugs of this group are produced 
by the Ukrainian industry. Analyzing the range of drugs used for the treatment of herpes viral 
diseases by the composition of active substances, it was found that the largest share is in monocom-
ponent preparations (94 %). Medicines in the soft dosage forms make up only 8 %.
4. Discussion
Methods for preventing and treating diseases caused by viruses include the following ap-
proaches: synthetic drug therapy, immunotherapy, and a combination of these two methods. Given 
that the major in the treatment of viral diseases are the suppression of virus replication and the res-
toration of the immune response, the most appropriate to achieve the maximum therapeutic effect 
is the creation of drugs with different pharmacological actions, in particular combined [10]. One of 
the most acceptable and convenient to use are the soft dosage forms, as they provide a direct effect 
on the pathogens, reduce the symptoms of the disease (pain, inflammation, swelling), have a low 
risk of side effects compared with parenteral and oral drugs.
In scientific works [17, 21] organizational, economic and pharmacoeconomic aspects of 
providing herpes virus patients are covered. The conducted marketing analysis of drugs used for 
the treatment of herpes viral diseases at the pharmaceutical market of Ukraine complements and 
deepens previously conducted studies of this problem in Ukraine.
Study limitations. Study limitation were antibacterial drugs and immunomodulators, 
which can be administered in comorbidities, and it will be our further studies. 
Prospects for further research. Prospects for our further research will focus on determin-
ing the level of socio-economic availability of this group of medicines for patients and ATC/DDD 
analysis, by which it is possible to determine the drug consumption of the above group.
The results of the research can be useful for doctors, pharmacists, teachers of medical and 
pharmaceutical institutions.
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5. Conclusions
Marketing analysis of medicines used to the treatment of herpes viral diseases at the phar-
maceutical market of Ukraine showed that the range of medicines is limited (80 trade names). 
The main part of the market consist of tablets (70 %). The largest number of medicines (51 %) is 
producted by domestic manufacturers. The leaders among the analysed drugs in the composition of 
active substances are monocomponent drugs (94 %). The share of the soft dosage forms is only 8 % 
(“Gerpevir®” (PJSC “Kievmedpreparat”), “Agerp” (Joint Ukrainian-Spanish company “Sperk-
oUkraine”), “Acyk®” (Salutas Pharma GmbH, Germany), “Virolex” (KRKA, d.d., Novo mesto, 
Slovenia), “ZoviraxTM” (Glaxo Operations UK Limited, Great Britain), “Acyclostad®” (STADA Art- 
nimnittel AG, Germany).
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